MoonLake Immunotherapeutics shares surged 45% premarket after the FDA said the company can pursue approval of its hidradenitis suppurativa drug Sonelokimab without additional trials. The guidance allows MoonLake to submit a Biologic License Application in the second half of 2026 using existing clinical data, significantly reducing development risk.